Eurofins Discovery 提供抗体药物偶联物(ADC)从概念到临床的一体化开发平台
ADC Development from Concept to Clinic
Eurofins Discovery 提供覆盖全工作流的一体化抗体药物偶联物(ADC)开发平台。该平台整合连接子-载荷设计、生物偶联、纯化、药代分析(DAR)及功能评估。通过优化化学与生物特性,帮助降低开发风险并缩短 ADC 研发周期。

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery while minimizing off-target effects. Their potential in areas such as targeted cancer cell killing and targeted protein degradation has fueled significant growth, resulting in numerous FDA approvals and more than 100 ADCs currently in clinical development. However, ADC development remains complex and highly empirical, requiring careful optimization of linker chemistry, payload selection, bioconjugation strategies, drug-to-antibody ratio (DAR), stability, and overall antibody integrity.
The ADC journey begins with linker-payload synthesis and bioconjugation. Eurofins Discovery offers extensive expertise in the design and synthesis of linker technologies, including protease-sensitive, glycosidase-sensitive, pH-sensitive, PEGylated, branched, and shielding linkers. Payloads are manufactured in specialized high-containment facilities to ensure the safe handling of highly potent compounds. Multiple conjugation options are available, providing flexibility to explore different designs and generate ADCs with customized pharmacokinetic profiles, improved stability, and controlled DAR distributions.
Once conjugation is complete, ADCs undergo purification using a range of chromatography techniques. These methods remove unconjugated antibodies, excess linker-payload materials, and aggregates to produce highly pure ADC preparations. This is essential for more reliable downstream analyses and ensures more accurate assessment of ADC performance.
DAR analysis is then conducted using high-resolution liquid chromatography-mass spectrometry (LC-MS). This approach confirms linker-payload incorporation, identifies individual DAR species, and provides detailed insights into ADC homogeneity. Such information is critical for optimizing product consistency, efficacy, safety, and manufacturability.
Finally, a comprehensive suite of biochemical, functional, and cytotoxicity assays is essential to characterize ADC candidates. Data-driven assessment of binding, biological function, and therapeutic potential, through both in vitro and in vivo studies, helps identify the most promising candidates for further advancement and development.
Eurofins Discovery provides a fully integrated ADC development platform spanning every stage of the workflow, from linker-payload design through analytical characterization and functional assessment. By leveraging deep expertise in chemistry, biochemistry, and antibody optimization and characterization, Eurofins Discovery scientists help mitigate development risks and shorten timelines while optimizing ADC safety, efficacy, and manufacturability.
The post ADC Development from Concept to Clinic appeared first on GEN - Genetic Engineering and Biotechnology News.
来源:GEN Genetic Engineering & Biotech · genengnews.com